Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
Abstract Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as “blast-phase MPN”, is the most feared disease complication, with incidence estimates of 1–4% for essential thrombocythemia, 3–7% for polycythemia vera, and 9–13% for primary myelofibrosis. Diagnosis of MPN-BP...
Main Authors: | Ayalew Tefferi, Hassan Alkhateeb, Naseema Gangat |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2023-07-01
|
Series: | Blood Cancer Journal |
Online Access: | https://doi.org/10.1038/s41408-023-00878-8 |
Similar Items
-
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
by: Rimal Ilyas, et al.
Published: (2023-02-01) -
Targeted next-generation sequencing in blast phase myeloproliferative neoplasms
by: Terra L. Lasho, et al.
Published: (2018-02-01) -
Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
by: Maymona G. Abdelmagid, et al.
Published: (2023-02-01) -
Sodium-glucose co-transporter-2 inhibitor treatment-associated changes in hemoglobin level in anemic patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
by: Ali Alsugair, et al.
Published: (2025-01-01) -
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points
by: Naseema Gangat, et al.
Published: (2020-11-01)